Skip to main content
Filing year 2024

EVAN'S VICTORY AGAINST NEUROBLASTOMA FOUNDATION INC

Germantown, Maryland·EIN 45-2922166·NTEE G98 · Diseases, Disorders & Medical Disciplines·501(c)(3)
Total revenue
$469k
Total assets
$564k
Total expenses
$392k
Reported officers
9
Mission

TO SUPPORT CHILDHOOD CANCER RESEARCH AND PATIENT AND SURVIVOR WELLNESS PROGRAMS.

Executive compensation

Form 990 · Part VII & Schedule J · 2 reported individuals · Filing year 2024

Percentile bands compare each position's total pay with the same role at Diseases, Disorders & Medical Disciplines organizations in Maryland.

President
25th percentile to median
$69k
$73k
Treasurer
Officer (Unspecified)
$68k
$73k

Teal figures restate each filed amount in 2026 dollars.

Estimated with Washington-Arlington-Alexandria, DC-VA-MD-WV metro-area CPI-U, restating filed pay into May 2026 dollars. A restatement of past pay, not current or projected pay.

Plus 7 unpaid individuals.

Browse compensation in Diseases, Disorders & Medical Disciplines

Pay in context

Top pay as a share of expenses

In 2024, the highest total compensation at EVAN'S VICTORY AGAINST NEUROBLASTOMA FOUNDATION INC equaled 18% of the organization's total expenses. The median for diseases, disorders & medical disciplines organizations is 10%.

This organization (2024)
18%
Sector median
10%
Middle half of sector
4% to 22%

Based on 2,393 diseases, disorders & medical disciplines organizations, each measured at its most recent filing year with reported expenses and compensation.

Funded by

Private foundations whose Form 990-PF Part XV grants matched this organization.

Held steady
from 2023

From $70k in 2023 to $69k in 2024.

$70k
2023
$69k
2024
In today's dollarsEst.
Down 4% in real terms$76k to $73k

Estimated with Washington-Arlington-Alexandria, DC-VA-MD-WV metro-area CPI-U, restating filed pay into May 2026 dollars. A restatement of past pay, not current or projected pay.

Pay for the position

Chief Executive Officer pay fell 1% from 2023 to 2024, while revenue rose 34%.

$70k in 2023 to $69k in 2024.

Pay for the position itself, not any one person. The officeholder may have changed between 2023 and 2024.

Highest reported compensation in each year. Volunteer board members and partial-year payouts are filtered out.

Among peers

Revenue and top compensation, plotted against similar organizations. This organization is highlighted in cyan.

FAQ

Common questions about EVAN'S VICTORY AGAINST NEUROBLASTOMA FOUNDATION INC

What does the Chief Executive Officer of EVAN'S VICTORY AGAINST NEUROBLASTOMA FOUNDATION INC earn?

In 2024, the Chief Executive Officer of EVAN'S VICTORY AGAINST NEUROBLASTOMA FOUNDATION INC received $68,912 in total compensation. This pay is below the median (the midpoint) for Chief Executive Officer roles among Diseases, Disorders & Medical Disciplines organizations in Maryland, but above the bottom quarter of comparable filings. Based on IRS Form 990 data.

How does Chief Executive Officer pay at EVAN'S VICTORY AGAINST NEUROBLASTOMA FOUNDATION INC compare with similar nonprofits?

Compared with the same role at Diseases, Disorders & Medical Disciplines organizations in Maryland, the 2024 pay of the Chief Executive Officer at EVAN'S VICTORY AGAINST NEUROBLASTOMA FOUNDATION INC falls between the 25th percentile and the median. In 2024, the highest total compensation at EVAN'S VICTORY AGAINST NEUROBLASTOMA FOUNDATION INC equaled 18% of the organization's total expenses. The median for diseases, disorders & medical disciplines organizations is 10%.

What are EVAN'S VICTORY AGAINST NEUROBLASTOMA FOUNDATION INC's revenue and expenses?

In 2024, EVAN'S VICTORY AGAINST NEUROBLASTOMA FOUNDATION INC reported $469k in total revenue and $392k in total expenses on its IRS Form 990.

Free, forever
Build lists. Save your benchmarks.
A free Lucido account lets you build lists of nonprofits and save your search filters. No credit card.
Already a member? Sign in
Build a benchmark

Compare any role, sector, or revenue band

Build your own benchmark from millions of reported positions.